Beyond Weight Loss: New Drugs Ease Sleep Apnoea and Arthritis as Firms Push Monthly Shots

The contours of the next chapter in obesity pharmacotherapy are becoming clearer: drugs that not only shed pounds but also ameliorate serious comorbidities, and a concerted push to make treatment less burdensome. Eli Lilly’s experimental retatrutide has demonstrated in Phase 3 trials a 60.6 per cent reduction in moderate-to-severe obstructive sleep apnoea severity and up to 73.1 per cent relief from knee osteoarthritis pain among adults with obesity. Presented at the American Diabetes Association conference in New Orleans, the data position retatrutide as a potential multi-target therapy that could outflank existing weekly injectables like Lilly’s own Zepbound, already approved for sleep apnoea.

The drive for convenience is equally fierce. Pfizer and Amgen are advancing monthly GLP-1 receptor agonist formulations, a departure from the current weekly standard set by Wegovy and Zepbound. As Dr Christopher McGowan, a North Carolina gastroenterologist, notes, the frequency of dosing directly correlates with missed doses and treatment abandonment. “The more frequently a medication must be taken, the more opportunities there are to miss doses or stop treatment altogether,” he told NBC News. From London, analysts observe that improving adherence could unlock massive commercial potential in a global market already worth tens of billions.

For Pfizer, the bet is existential. After early stumbles in obesity research, the New York-based drugmaker acquired Metsera Inc. for $10 billion last year, signalling a renewed commitment to challenge first-movers Novo Nordisk and Eli Lilly. Executives now speak of a pipeline that extends beyond weight reduction to a constellation of related metabolic conditions, hoping to carve out a leadership position by the next decade. The strategy, viewed from Washington, reflects an understanding that obesity is a chronic disease requiring long-term management, much like hypertension or diabetes.

Yet for patients in much of the world, the promise of these medicines is undercut by cost. A national survey of 1,067 Brazilian physicians conducted by the IFEPEC institute for the pharmacy association Febrafar found that high price, not side effects or efficacy, is the main reason patients discontinue GLP-1 therapies. In Brazil, where the public health system does not cover such drugs for obesity, many patients cycle on and off treatment, undermining clinical outcomes. This mirrors concerns across Latin America, Africa, and large parts of Asia, where even the cheapest generics remain out of reach.

As the science advances and dosing intervals lengthen, the industry faces a paradox: while pharmaceutical innovation is producing ever more powerful and convenient tools to combat a global epidemic, the chasm between those who can afford them and those who cannot widens. The next frontier, health economists in Geneva argue, will not be a new molecular target or a monthly injection, but the design of affordable access models that can translate clinical breakthroughs into population-level health gains.